Protein kinase D as a potential chemotherapeutic target for colorectal cancer

Molecular Cancer Therapeutics

Volumn 13, Issue 5, 2014, Pages 1130-1141

  Wei, Ning ^a,b   Chu, Edward ^a,b   Wipf, Peter ^b,c   Schmitz, John C ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CID 755673; CRT 0066101; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KB NB 142 70; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE D; PROTEIN KINASE D 1; PROTEIN KINASE D 2; PROTEIN KINASE D3; PROTEIN SERINE THREONINE KINASE INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SIZE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; M PHASE CELL CYCLE CHECKPOINT; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE; COLORECTAL NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION; GENETICS; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HUMANS; MICE; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899874467     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0880     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Chu E. An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin Colorectal Cancer 2012;11:1-13.
3. Kohne CH, Lenz HJ. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist 2009;14: 478-88.
4. Lucas AS, O'Neil BH, Goldberg RM. A decade of advances in cytotoxic chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer 2011;10:238-44.
5. Diaz LA Jr., Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486:537-40.
6. Rozengurt E, Rey O, Waldron RT. Protein kinase D signaling. J Biol Chem 2005;280:13205-8.
7. Rozengurt E. Protein kinaseDsignaling: multiple biological functions in health and disease. Physiology 2011;26:23-33.
8. LaValle CR, George KM, Sharlow ER, Lazo JS, Wipf P, Wang QJ. Protein kinase D as a potential new target for cancer therapy. BBA Rev Cancer 2010;1806:183-92.
9. Eiseler T, Doppler H, Yan IK, Goodison S, Storz P. Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasion. Breast Cancer Res 2009;11:R13.
10. Trauzold A, Schmiedel S, Sipos B, Wermann H, Westphal S, Roder C, et al. PKCmu prevents CD95-mediated apoptosis and enhances proliferation in pancreatic tumour cells. Oncogene 2003;22: 8939-47.
11. Azoitei N, Pusapati GV, Kleger A, Moller P, Kufer R, Genze F, et al. Protein kinase D2 is a crucial regulator of tumour cell-endothelial cell communication in gastrointestinal tumours. Gut 2010;59: 1316-30.
12. Chen J, Deng F, Singh SV, Wang QMJ. Protein kinase D3 (PKD3) contributes to prostate cancer cell growth and survival through a PKC epsilon/PKD3 pathway downstream of Akt and ERK 1/2. Cancer Res 2008;68:3844-53.
13. Azoitei N, Kleger A, Schoo N, Thal DR, Brunner C, Pusapati GV, et al. Protein kinase D2 is a novel regulator of glioblastoma growth and tumor formation. Neuro Oncol 2011;13:710-24.
14. Harikumar KB, Kunnumakkara AB, Ochi N, Tong Z, Deorukhkar A, Sung B, et al. A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther 2010;9:1136-46.
15. Lavalle CR, Bravo-Altamirano K, Giridhar KV, Chen J, Sharlow E, Lazo JS, et al. Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility. BMC Chem Biol 2010;10:5.
16. Sharlow ER, Giridhar KV, LaValle CR, Chen J, Leimgruber S, Barrett R, et al. Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone. J Biol Chem 2008;283:33516-26.
17. Guo J, Clausen DM, Beumer JH, Parise RA, Egorin MJ, Bravo-Altamirano K, et al. In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts. Cancer Chemother Pharmacol 2013;71:331-44.
18. Gamber GG, Meredith E, Zhu QM, Yan WL, Rao C, Capparelli M, et al. 3,5-Diarylazoles as novel and selective inhibitors of protein kinase D. Bioorg Med Chem Lett 2011;21:1447-51.
19. Sharlow ER, Wilson GM, Close D, Leimgruber S, Tandon M, Reed RB, et al. Discovery of diverse small molecule chemotypes with cell-based PKD1 inhibitory activity. PLoS ONE 2011;6:e25134.
20. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282:1497-501.
21. Park JG, Oie HK, Sugarbaker PH, Henslee JG, Chen TR, Johnson BE, et al. Characteristics of cell lines established from human colorectal carcinoma. Cancer Res 1987;47:6710-8.
22. Wei N, Liu GT, Chen XG, Liu Q, Wang FP, Sun H. H1, a derivative of tetrandrine, exerts anti-MDR activity by initiating intrinsic apoptosis pathway and inhibiting the activation of Erk1/2 and Akt1/2. Biochem Pharmacol 2011;82:1593-603.
23. Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, et al. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res 2012;72:3499-511.
24. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
25. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009;361:2449-60.
26. Guha S, Tanasanvimon S, Sinnett-Smith J, Rozengurt E. Role of protein kinase D signaling in pancreatic cancer. Biochem Pharmacol 2010;80:1946-54.
27. Borges S, Storz P. Protein kinase D isoforms: new targets for therapy in invasive breast cancers? Expert Rev Anticancer Ther 2013;13:895-8.
28. Sinnett-Smith J, Rozengurt N, Kui R, Huang C, Rozengurt E. Protein kinase D1 mediates stimulation of DNA synthesis and proliferation in intestinal epithelial IEC-18 cells and in mouse intestinal crypts. J Biol Chem 2011;286:511-20.
29. Kim M, Jang HR, Kim JH, Noh SM, Song KS, Cho JS, et al. Epigenetic inactivation of protein kinase D1 in gastric cancer and its role in gastric cancer cell migration and invasion. Carcinogenesis 2008;29:629-37.
30. Kienzle C, Eisler SA, Villeneuve J, Brummer T, Olayioye MA, Hausser A. PKD controls mitotic Golgi complex fragmentation through a Raf- MEK1 pathway. Mol Biol Cell 2013;24:222-33.
31. Sinnett-Smith J, Zhukova E, Hsieh N, Jiang X, Rozengurt E. Protein kinase D potentiates DNA synthesis induced by Gq-coupled receptors by increasing the duration of ERK signaling in Swiss 3T3 cells. J Biol Chem 2004;279:16883-93.
32. Storz P, Doppler H, Toker A. Protein kinaseDmediates mitochondrionto- nucleus signaling and detoxification from mitochondrial reactive oxygen species. Mol Cell Biol 2005;25:8520-30.
33. Chiu TT, Leung WY, Moyer MP, Strieter RM, Rozengurt E. Protein kinase D2 mediates lysophosphatidic acid-induced interleukin 8 production in nontransformed human colonic epithelial cells through NFkB. Am J Physiol Cell Physiol 2007;292:C767-77.
34. Mihailovic T, Marx M, Auer A, Van Lint J, Schmid M, Weber C, et al. Protein kinase D2 mediates activation of nuclear factor kBbyBcr-Abl in Bcr-Abl human myeloid leukemia cells. Cancer Res 2004;64: 8939-44.
35. Meredith EL, Ardayfio O, Beattie K, Dobler MR, Enyedy I, Gaul C, et al. Identification of orally available naphthyridine protein kinase D inhibitors. J Biol Chem 2010;53:5400-21.
36. Caldwell JJ, Welsh EJ, Matijssen C, Anderson VE, Antoni L, Boxall K, et al. Structure-based design of potent and selective 2-(quinazolin-2- yl)phenol inhibitors of checkpoint kinase 2. J Med Chem 2011;54: 580-90.
37. Ekambaram R, Enkvist E, Vaasa A, Kasari M, Raidaru G, Knapp S, et al. Selective bisubstrate inhibitors with sub-nanomolar affinity for protein kinase Pim-1. ChemMedChem 2013;8:909-13.
38. Nagarajan S, Doddareddy M, Choo H, Cho YS, Oh KS, Lee BH, et al. IKKb inhibitors identification part I: homology model assisted structure based virtual screening. Bioorg Med Chem 2009;17: 2759-66.
39. Park H, Chi O, Kim J, Hong S. Identification of novel inhibitors of tropomyosin-related kinase A through the structure-based virtual screening with homology-modeled protein structure. J Chem Inf Model 2011;51:2986-93.
40. LaValle CR, Zhang LY, Xu SP, Eiseman JL, Wang QJ. Inducible silencing of protein kinase D3 inhibits secretion of tumor-promoting factors in prostate cancer. Mol Cancer Ther 2012;11: 1389-99.